Please login to the form below

Not currently logged in
Email:
Password:

Sanofi appoints Bill Sibold to lead its Genzyme business

He will succeed David Meeker, who is leaving in the firm in June

Sanofi_Genzyme_Bill_SiboldSanofi has appointed Bill Sibold as executive vice president for Sanofi Genzyme in a move that will also see he join the company's executive committee.

Previously head of Sanofi Genzyme’s multiple sclerosis, oncology and immunology organisation, Sibold has experience in leading global therapy launches.

Prior to Sanofi, Sibold has held a number of leadership positions for biopharmaceutical companies such as Biogen, Avanir Pharmaceuticals and Eli Lilly.

Oliver Brandicourt, chief executive officer at Sanofi, said: “With a strong commitment to serving patients, Sanofi Genzyme has evolved from a rare disease company into a preeminent specialty care business, deeply rooted in science.

“I am confident in Bill’s experience and leadership to build on this strong foundation as we chart the next chapter for Sanofi Genzyme, which has become a real growth driver for Sanofi.”

Sibold will succeed David Meeker, who will leave the company at the end of June.

7th April 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...

Infographics